Replies to post #237500 on Biotech Values

[DewDiligence]

PFE/LLY—FDA panel votes 19-1 against approval of Tanezumab for osteoarthritis pain:

https://finance.yahoo.com/news/joint-fda-advisory-committee-votes-195000233.html

No investors or analysts I know of had non-zero sales projections for this drug.